Designing a Bayesian Model of the Plasma Clearance of Calcium Edetate de Sodium for the Calculation of GFR and Validity Compared to the Renal Clearance of Inulin

PHASE3CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2017

Conditions
Kidney Disease
Interventions
DRUG

Dosage of Calcium edetate de sodium

There is no medical data for the use of Calcium edetate de sodium as a tracer to assess GFR. Calcium edetate de sodium is a treatment for lead intoxication. The extension of use as a tracer comes from its exclusive elimination by glomerular filtration. Plasma and renal clearance of Calcium edetate de sodium and Inulin will be measured for every included patient during a hospital day care (V1). For transplanted patients, plasma clearance of Calcium edetate de sodium will be repeated within one week (more or less 48hours) during annual medical check-up of renal transplantation.

Trial Locations (1)

87 042

University Hospital, Limoges

All Listed Sponsors
lead

University Hospital, Limoges

OTHER

NCT02300376 - Designing a Bayesian Model of the Plasma Clearance of Calcium Edetate de Sodium for the Calculation of GFR and Validity Compared to the Renal Clearance of Inulin | Biotech Hunter | Biotech Hunter